174 related articles for article (PubMed ID: 24994597)
1. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE; Unger JM; Sosman JA; Flaherty LE; Tuthill RJ; Porter MJ; Thompson JA; Kempf RA; Othus M; Ribas A; Sondak VK
Cancer Immunol Res; 2014 Oct; 2(10):981-7. PubMed ID: 24994597
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
3. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
6. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
7. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
10. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
11. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
13. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Sondak VK; Liu PY; Tuthill RJ; Kempf RA; Unger JM; Sosman JA; Thompson JA; Weiss GR; Redman BG; Jakowatz JG; Noyes RD; Flaherty LE
J Clin Oncol; 2002 Apr; 20(8):2058-66. PubMed ID: 11956266
[TBL] [Abstract][Full Text] [Related]
15. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
16. Melanoma: is immunotherapy of benefit?
Faries MB; Morton DL
Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
[No Abstract] [Full Text] [Related]
17. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
[TBL] [Abstract][Full Text] [Related]
20. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E
Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
